ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TFX
HAE (74) STVN (54) MMSI (68) MMED (44) ⌘ Pro Terminal →

Teleflex Incorporated (TFX) — RQD Stock Rating Cockpit

$140.67 +0.64% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $140.56

Teleflex Incorporated (TFX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.92B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TFX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Teleflex Incorporated (NYSE: TFX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $140.67 (+0.64% 1D, market cap $5.92B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TFX ranks #284 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TFX compare to HAE and STVN in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), TFX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 56.2%, and ROIC of 1.8%. By comparison, HAE (Haemonetics Corporation) holds a B grade (74/100 RQD, P/E N/A, ROIC 8.4%, cap $5.44B) and STVN (Stevanato Group S.p.A.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.29B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TFX?
▼

Per TFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000096943), Teleflex Incorporated generated $1.99B in revenue (+17.2% YoY), -$905.6M in net income, and $0 in free cash flow against $6.95B in total assets and $2.54B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $140.57 (-0.07%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 1.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (6)Whales (17)SEC (9)Macro (11)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$159 Bull$134 Base$105 Bear
📬 FREE TFX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TFX)Realized 20D OHLCV Swing Band: ±5.4%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY TFX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (35% of score)

20D Institutional Volume Accumulation (±5.4% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (23% of score)

FRED Regime × Technicals: 90% of 52W Range • RSI-14 at 64.8 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$123.29+5.8% Next Q
Q2 (-2Q)
43
Grade D$130.40+6.6% Next Q
Q3 (-1Q)
45
Grade D$138.98+1.2% Next Q
Current
48
Grade D$140.67-5.6% Hist 90D α
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TFX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TFX currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($131.44) and Max Pain ($147.70) forces dealer call-delta covering toward $158.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TFX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TFX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
64.830 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.12>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE90% OF RANGE
L: $100$140.67H: $145
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on TFX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

1.8% ROIC with 56.2% gross margin and -18.00% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (45)

Altman-Z 2.12 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (55)

22/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like TFX
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TFX)

  • ✓Walkthrough of TFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TFX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.33%⚡ TESTING RESISTANCE
2026-11-03O $141.4H $141.4L $139.8C $140.7VOL 891.3K
RES: $142.8SUP: $117.2SMA50: $131.4SMA200: $125.7
$146.9$139.1$131.4$123.6$115.9RES $142.8SUP $117.2$140.72026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TFX Butterfly Map → + Track TFX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
20.6%/yr Implied 5Y Growth

vs. +17.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TFX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TFX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TFX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TFX)

Health Care Rank #284 of 1015 ⚔️ HAE vs TFX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TFX vs. HAE, STVN, MMSI, MMED)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Teleflex Incorporated (TFX) ranks #284 by composite RQD confidence (48/100, grade D) and #145 by equity capitalization ($5.92B). Within this direct 5-issuer industry benchmark cohort, MMSI leads on earnings valuation at 43.4x trailing P/E, while HAE leads on capital efficiency and profitability with 8.4% ROIC and 59.0% gross margin. HAE currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with TFX at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TFX ACTIVE
Teleflex Incorporated
D 48/100 — 56.2% 1.8% +0.64% $5.92B Benchmark Subject
HAE
Haemonetics Corporation
B 74/100 — 59.0% 8.4% +0.41% $5.44B /hae-vs-tfx →
STVN
Stevanato Group S.p.A.
D+ 54/100 — — — +1.86% $5.29B /stvn-vs-tfx →
MMSI
Merit Medical Systems Inc.
C+ 68/100 43.4x 48.7% 7.8% -2.24% $5.17B /mmsi-vs-tfx →
MMED
MiniMed Group Inc.
D 44/100 — 54.2% -3.9% +3.39% $5.14B /mmed-vs-tfx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000096943 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Teleflex Incorporated (TFX) reported GAAP revenue of $1.99B (+17.2% vs. FY2024 revenue of $1.70B , and +16.4% cumulative change since FY2023) , GAAP net income of -$905.6M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, TFX closed FY2025 with $6.95B in total assets against $2.54B in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.99B -$905.6M — — $6.95B $2.54B
FY2024 (FY) 2024-12-31 $1.70B $70.2M — — $7.10B $1.56B
FY2023 (FY) 2023-12-31 $1.71B $357.6M — — $3.30B $771.0M

3. TFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Teleflex Incorporated (NYSE: TFX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $140.67 (+0.64% 1D, market cap $5.92B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TFX ranks #284 in composite RQD confidence.

How does TFX compare to HAE and STVN in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), TFX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 56.2%, and ROIC of 1.8%. By comparison, HAE (Haemonetics Corporation) holds a B grade (74/100 RQD, P/E N/A, ROIC 8.4%, cap $5.44B) and STVN (Stevanato Group S.p.A.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.29B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TFX?

Per TFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000096943), Teleflex Incorporated generated $1.99B in revenue (+17.2% YoY), -$905.6M in net income, and $0 in free cash flow against $6.95B in total assets and $2.54B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TFX trading relative to its 50-day, 200-day, and 52-week technical levels?

TFX last traded at $140.67 (+0.64% on volume of 923,140 shares), positioning the stock +7.02% above its 50-day simple moving average ($131.44) and +11.88% above its 200-day simple moving average ($125.73). Across its 52-week range of $100.18 to $145.00, TFX sits at the 90.3% percentile with a 14-day RSI of 64.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.4% ($133.07 to $148.27).

Direct Sub-Reports: TFX RQD Cockpit TFX 12M Forecast TFX Earnings & Move TFX Dividends & DRIP TFX Insiders & 13F TFX Whale Options TFX Profit Sankey TFX News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

TFX — Teleflex Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Teleflex Incorporated (TFX) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $140.67 (+0.64% 1D, market capitalization $5.92B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of 1.8%, gross margin of 56.2%, operating margin of 5.9%, and free cash flow yield of -18.00%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (9/20): Incorporates a 0.98x equity beta, Altman Z-Score of 2.12, Piotroski F-Score of 4/9, and Debt/Equity of 0.81x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Teleflex Incorporated is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. FY 2025 revenue was $1.99B and gross margin was 56.2% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Teleflex Incorporated (TFX) reported $1.99B in annual revenue (up from $1.70B in FY2024, +17.2% YoY) and -$905.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.71B revenue, $357.6M net income) through FY2025, TFX scaled operating cash flow to $0 and free cash flow to $0, backed by $6.95B in total assets against $2.54B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -18.00% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $100.18 – $145.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 40.9x EV/EBITDA against 5.9% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), TFX carries a macro regime beta of 0.98 and gross margin of 56.2%.

  • Key Question #1: Can TFX sustain or expand its 5.9% operating margin and 1.8% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.99B and free cash flow of $0, how will capital allocation balance growth reinvestment against $2.54B in total debt?
  • Key Question #3: How sensitive is TFX's 27.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

TFX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Teleflex Incorporated (TFX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TFX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TFX Bull vs. Bear Conversation Board — What's Your Call at $140.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TFX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TFX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $178.91 (+28.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17 of 20, the strongest pillar in the Roarable rating.

Picked up a starter position in TFX in my $100K Virtual Cash book at $139.77. Institutional accumulation and options positioning score 17 of 20, the strongest pillar in the Roarable rating.. Trading inside a $100.18–$145.00 52-week range with -18.0% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 17/20 institutional whale-flow stock at $139.77 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $110.42 (-21.0%)
Spot @ $139.77

ROIC of 1.8% and FCF yield of -18% leave the fundamental cash engine at 6 of 20 against a forward P/E of 27.

ROIC of 1.8% and FCF yield of -18% leave the fundamental cash engine at 6 of 20 against a forward P/E of 27.. Look at the math on TFX: paying 27.0x forward P/E for 1.8% ROIC and 5.9% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $123.00 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%